pharma · Advanced Solid Tumor · Acute Myeloid Leukemia or Myelodysplastic Syndromes · APRE
Aprea Therapeutics
Aprea Therapeutics patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US
- Employees
- 15
- Programs
- 15
- Drugs
- 5
- Patents
- 6
Aprea Therapeutics patents
6 pharmaceutical patents indexed for Aprea Therapeutics. 1 expire within 24 months.
Aprea Therapeutics has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9061016
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
granted -
US 7902167
Compounds and methods for down-regulating Wrap53 protein by RNA interference
granted -
US 7759361
Azabicyclooctan-3-one derivatives and use thereof
granted -
US 7659278
Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
granted -
US 7348330
1-azabicyclo [2,2,2] octan-3-one derivatives
granted -
US 6921765
1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
expired
Frequently asked questions
How many patents does Aprea Therapeutics have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Aprea Therapeutics patents expire?
1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.